Vinorelbine could be a useful second-line treatment for patients with relapsed mesothelioma. A phase II clinical trial examined vinorelbine to see how effective it is in patients who had their pleural mesothelioma progress after platinum chemotherapy treatment. Doctors believe vinorelbine could be another option for patients instead of the standard[…]
Keytruda
Researchers are Developing a Test to Determine Which Mesothelioma Patients Will Benefit From Immunotherapy
Doctors want to figure out which pleural mesothelioma patients will best benefit from certain chemotherapy drugs. Currently there are no tests to see what immunotherapy drugs might work on a specific patient. This leads to doctors trying out different treatments that have negative side effects to only find out the[…]
Cholesterol Drugs Called Statins Could Help Extend Mesothelioma Sufferers’ Lives
A group of drugs called statins used for controlling cholesterol are showing that they can help mesothelioma patients taking PD-1 inhibitors survive longer. Researchers in Italy and the Netherlands found this information in an international study of 250 patients. The patients studied either had pleural mesothelioma or non-small cell lung[…]
The ONCOS-102 Vaccine is Still Showing Promising Results
The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of[…]
Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma
A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding[…]
A New Study is Looking at the Combination of Keytruda and ONCOS-102
A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but[…]
A Combination of Immunotherapy Drugs Could Help Mesothelioma Patients
Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]
Keytruda is Now Approved for Mesothelioma and Other Cancers
Keytruda is now approved for certain mesothelioma patients. The immunotherapy drug has been tested for mesothelioma before, but has not been approved for the treatment of it. The approval is for adult and pediatric cancers with unresectable disease and high mutational burden that have been treated and have no other[…]
Dendritic Cell Therapy Could be used to Treat Mesothelioma
Immunotherapy is a blossoming field that is becoming more advanced. Instead of other treatments that kill healthy cells in addition to killing cancerous cells, immunotherapy uses the body’s immune system to fight cancer cells, leaving healthy non-cancerous cells intact. It is a better treatment because it is very effective, more[…]
Less than Half of Cancer Patients Eligible for Immunotherapy Treatments
In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer. It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma.[…]
